Skip to content

21-063 - Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

Status: open

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Treatment for Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Contact Us


This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Providers Associated With This Trial

Principle Investigator

  • Omar AlkharabshehView Profile
    Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology; Associate Program Director, Medical Oncology Fellowship

Sub Investigators

  • Persing brianView Profile
    Brian E. Persing, M.D.Medical Oncologist and HematologistDivision Director, Medical Oncology; Arlene and Mayer Mitchell Chair of Medical Oncology; Program Director, Medical Oncology Fellowship; Assistant Professor of Medical Oncology
This link will open in a new tab or window.